# Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing

- Link: https://www.directorstalkinterviews.com/syncona-portfolio-company-beacon-therapeutics-raises-170-million-in-a-series-b-financing/4121163604
- Published: 2024-07-03T07:45:00+01:00
- Author: Ethan Davis

**Syncona Ltd** (LON:SYNC) a leading life science investor focused on creating, 
building and scaling global leaders in life science, has today announced that it
has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series
B financing of its portfolio company Beacon Therapeutics, a leading ophthalmic gene
therapy company with a purpose to save and restore the vision of patients with blinding
retinal diseases. Forbion led the round and, alongside Syncona, the financing was
supported by existing investors Oxford Science Enterprises and the University of
Oxford, and new investors TCGX and Advent Life Sciences.

 * Syncona invests in Beacon’s $170 million (£134 million^([1])) Series B financing,
   committing $42.5 million (£33.5 million), alongside a leading global syndicate
   of new and existing investors

 * Syncona’s holding in Beacon written up by £14.1 million (2.2p per share); a 17.6
   per cent uplift to the 31 March 2024 valuation of the company

 * Including new capital invested, Syncona’s holding value of Beacon will be $131.9
   million (£104.0 million), and on drawdown of the full Series B financing, Syncona’s
   ownership stake in the business will be 41.4 per cent^([2])

Syncona launched Beacon in 2023, cornerstoning a Series A financing. Beacon was 
created to pursue an opportunity Syncona identified to apply its domain knowledge
in retinal disease to a late-stage clinical asset through the acquisition of AGTC
^([3]) in 2022, which it complemented with a pipeline of pre-clinical programmes
to build a leading retinal gene therapy company. Beacon is focused on both rare 
and prevalent diseases, including X-linked retinitis pigmentosa (XLRP), a blinding
orphan disease for which there is no available treatment and dry age-related macular
degeneration (dAMD), a leading cause of irreversible vision loss in people over 
60. Beacon’s lead asset, AGTC-501, is currently in a Phase II/III registrational
trial^([4]) for the treatment of XLRP, which is expected to read out in CY2026. 
Beacon presented encouraging 12-month efficacy data from the Phase II SKYLINE trial
of AGTC-501 during the year, and 24-month data is expected in H2 CY2024.

This latest financing brings the total amount that Beacon has raised in funding 
to date to approximately $290 million. The funds will be used to support the continued
clinical development of AGTC-501 for XLRP and to generate Phase I/II clinical trial
data for Beacon’s dAMD programme.

Following the Series B financing, Syncona’s holding in Beacon has been written up
by £14.1 million, a 17.6 per cent uplift to the 31 March 2024 valuation of the company.
Including £9.6 million of new capital invested since 31 March 2024, Syncona’s holding
value of Beacon will be $131.9 million (£104.0 million). In addition, Syncona has
an existing £14.4 million of value attributed to a deferred consideration from the
prior acquisition of AGTC^([5]). On drawdown of the full Series B financing, Syncona’s
ownership stake in the business will be 41.4 per cent.

**Elisa Petris, Lead Partner at Syncona Investment Management Limited and Board 
Director of Beacon Therapeutics, said:** “Beacon has secured a high-quality syndicate
of investors to support the ongoing development of its lead clinical candidate AGTC-
501 and broader pipeline. The strength and calibre of this global group of life 
science investors provides important external validation of Beacon’s technology 
and progress to date. We have leveraged our expertise and network to support Beacon
thus far, from identifying the opportunity to acquire a late-stage asset in AGTC,
to supporting this financing today. We look forward to continuing to work closely
with the company and our syndicate partners to advance its solutions for debilitating
blinding retinal diseases through the clinic and towards patients.”

**David Fellows, Chief Executive Officer of Beacon Therapeutics, said:** “We are
focused on progressing our promising pipeline of ocular gene therapies to save and
restore the vision of patients with a range of prevalent and rare retinal diseases
that result in blindness. These funds will support the ongoing development of our
late-stage and preclinical pipeline and enable acceleration of the development of
AGTC-501, as we progress through the clinic and toward commercialisation. We are
delighted to extend our strong group of investors and look forward to working with
them to ambitiously pursue our strategy.”

Notes:

^([1]) FX rates at 2 July 2024.

^([2]) Percentage holding reflects Syncona’s ownership stake at the point full current
commitments are invested.

^([3]) Applied Genetic Technologies Corporation.

^([4]) The UK’s MHRA and the EU’s EMA have accepted the Phase II/III VISTA study
design as being pivotal.

^([5]) As part of Syncona’s acquisition of AGTC, the Company has the potential to
benefit from any future commercialisation of Beacon’s lead asset AGTC-501 via a “
deferred consideration” which provides the right to a mid-single digit percentage
of future income from sales and licensing. Milestone value stated at 31 March 2024.

Share on:
